Apixaban, an oral anticoagulant, is currently the subject of research into new formulations [1]. These investigational formulations aim to potentially improve drug delivery, patient convenience, or therapeutic outcomes [1].
What is Apixaban Used For?
Apixaban is prescribed to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation [2]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [2].
Are There Different Types of Apixaban Formulations Being Studied?
Research is exploring various investigational formulations of apixaban. While specific details of all ongoing studies may not be publicly available, the focus of such investigations often includes developing alternative dosage forms or delivery systems [1]. This could involve exploring different strengths, extended-release mechanisms, or novel administration routes, although oral tablets are the current standard [1][2].
When Does the Patent for Apixaban Expire?
The patent landscape for apixaban is complex, with multiple patents covering the drug and its uses [3]. DrugPatentWatch.com tracks patent expirations and exclusivity periods, which can vary by region and specific patent [3]. Generally, primary patents for originator drugs begin to expire around this time, opening the door for generic competition [3].
Can Generic Apixaban Be Available Soon?
The availability of generic apixaban is directly linked to patent expirations and any ongoing legal challenges or exclusivity periods [3]. Once the relevant patents and exclusivities expire, generic manufacturers can seek regulatory approval to market their versions of apixaban [3]. DrugPatentWatch.com provides detailed information on these timelines and potential market entry dates for generics [3].
What Are the Risks of Apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding [2]. This can range from minor bruising to serious, life-threatening hemorrhages [2]. Other potential side effects include anemia and allergic reactions [2].
How Does Apixaban Work?
Apixaban is a direct factor Xa inhibitor [2]. Factor Xa is a crucial enzyme in the blood clotting cascade. By inhibiting factor Xa, apixaban reduces thrombin generation, which in turn prevents fibrin formation and the development of blood clots [2].
Who Makes Apixaban?
The original developer and marketer of apixaban is Bristol Myers Squibb, under the brand name Eliquis [2]. However, with patent expirations, other pharmaceutical companies may begin manufacturing generic versions [3].
Sources
1. DrugPatentWatch.com
2. Bristol Myers Squibb. Eliquis prescribing information.
3. DrugPatentWatch.com